Filtered By:
Drug: Clopidogrel

This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 1913 results found since Jan 2013.

Antiplatelet Use in Ischemic Stroke
CONCLUSIONS: Although good evidence exists for the use of certain antiplatelet agents postischemic stroke, there are considerable opportunities for future research to investigate personalized therapies. These include screening patients for platelet polymorphisms that confer antiplatelet resistance and for randomized trials including more racially diverse populations.PMID:35094598 | DOI:10.1177/10600280211073009
Source: The Annals of Pharmacotherapy - January 31, 2022 Category: Drugs & Pharmacology Authors: Marharyta Kamarova Sheharyar Baig Hamish Patel Kimberley Monks Mohammed Wasay Ali Ali Jessica Redgrave Arshad Majid Simon M Bell Source Type: research

Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients with Atrial Fibrillation: 2.3 Year Follow-Up of the PROTECT AF Trial.
CONCLUSIONS: The "local" strategy of LAA closure is noninferior to "systemic" anticoagulation with Warfarin. PROTECT AF has, for the first time, implicated the LAA in the pathogenesis of stroke in AF. CLINICAL TRIAL REGISTRATION INFORMATION: Clinicaltrials.gov; Unique Identifier: NCT00129545. PMID: 23325525 [PubMed - as supplied by publisher]
Source: Circulation - January 16, 2013 Category: Cardiology Authors: Reddy VY, Doshi SK, Siever H, Buchbinder M, Neuzil P, Huber K, Halperin JL, Holmes D Tags: Circulation Source Type: research

Clopidogrel High-on-Treatment Platelet Reactivity in Acute Ischemic Stroke Patients
Conclusions: Clopidogrel-HTPR was found in 44% of the patients with acute ischemic stroke. Besides time-dependency of the clopidogrel effect, major risk factors for clopidogrel-HTPR were diabetes mellitus and higher HbA1c values. Further investigations are required to analyse if a function test guided strategy has the potential to optimize the antiplatelet therapy of acute stroke patients.
Source: Thrombosis Research - January 9, 2014 Category: Hematology Authors: Saskia H. Meves, Kay D. Schröder, Heinz G. Endres, Christos Krogias, Jan C. Krüger, Horst Neubauer Tags: Platelets and cell biology Source Type: research

A Markov model to compare the long-term effect of aspirin, clopidogrel and clopidogrel plus aspirin on prevention of recurrent ischemic stroke due to intracranial artery stenosis
Conclusion: To prevent recurrent stroke in patients with intracranial artery stenosis, especially in those patients with a history of TIA or coronary artery disease, medical therapy with clopidogrel plus aspirin should be considered in preference to aspirin alone.
Source: Neurology India - March 7, 2014 Category: Neurology Authors: Jinqiu YangLukui ChenNaveen ChitkaraQiang Xu Source Type: research

rLOAD: does sex mediate the effect of acute antiplatelet loading on stroke outcome
Background: Biologic sex can influence response to pharmacologic therapy. The purpose of this proof-of-concept study was to evaluate the medicating effects of estrogen in the efficacy of acute antiplatelet loading therapy on stroke outcome in the rabbit small clot embolic model. Methods: Female and male (20/group) New Zealand White rabbits were embolized to produce embolic stroke by injecting small blood clots into the middle cerebral artery via an internal carotid artery catheter. Two hours after embolization, rabbits were treated with standard dose antiplatelet loading (aspirin 10 mg/kg plus clopidogrel 10 mg/kg). Primar...
Source: BioMed Central - July 15, 2014 Category: Journals (General) Authors: Dawn M MeyerJo-Ann EastwoodM Peggy ComptonKaren GylysJustin A Zivin Source Type: research

Antiplatelet Strategies for Secondary Prevention of Stroke and TIA
Abstract Stroke is a major public health issue, and stroke recurrence accounts for a quarter of all events. Antiplatelet therapy has been extensively studied for secondary stroke prevention and is established as effective in this high-risk population. Several agents have been evaluated in this setting, both in isolation and combination. The most widely used antiplatelet medications are aspirin, clopidogrel, and aspirin plus extended-release dipyridamole. However, new agents and combinations continue to be evaluated. A detailed review of the evidence supporting various antiplatelet regimens for secondary stroke pr...
Source: Current Atherosclerosis Reports - September 10, 2014 Category: Cardiology Source Type: research

Effects of Antiplatelet Agents on Functional Outcome and Cognitive Status in Patients with Acute Ischemic Stroke
Conclusion The use of antiplatelet agents in acute ischemic stroke may have a favorable effect on functional outcome and cognitive status in patients at 3 months poststroke.
Source: International Journal of Gerontology - November 17, 2014 Category: Geriatrics Source Type: research

rLOAD: does sex mediate the effect of acute antiplatelet loading on stroke outcome
Conclusions Behavioral outcomes are improved with females with higher endogenous estrogen levels treated with standard dose antiplatelet loading. This is the first non-rodent study to demonstrate that higher endogenous estrogen levels in female rabbits appear to be neuroprotective in ischemic stroke. This research supports the further study of the effect of endogenous estrogen levels on outcome with standard dose antiplatelet loading in stroke patients not eligible for revascularization therapies.
Source: Biology of Sex Differences - July 15, 2014 Category: Biology Source Type: research

Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk
Conclusion Left atrial appendage closure in patients with non-valvular atrial fibrillation and high risk for stroke and bleeding events effectively prevented stroke and reduced cerebral ischemic events compared to expected stroke rate according to CHA2DS2-VASc Score. Dual antiplatelet therapy for 3 months reduced the rate of bleeding events compared to 6 months therapy with no increase of thrombotic events.
Source: Clinical Research in Cardiology - August 29, 2015 Category: Cardiology Source Type: research

Combined clopidogrel-aspirin treatment for high risk TIA or minor stroke does not increase cerebral microbleeds.
CONCLUSIONS: For the treatment of high-risk TIA or minor stroke patients, the clopidogrel-aspirin treatment did not increase the number of CMB than Aspirin alone. It appears that the extent of CMB was associated with the extent of existing CMB occurred in previous stroke, which was mostly located in cortical, subcortical zone. PMID: 26391570 [PubMed - in process]
Source: Neurological Research - September 25, 2015 Category: Neurology Tags: Neurol Res Source Type: research

Controversies in antiplatelet therapy in the secondary prevention of stroke
Publication date: Available online 19 January 2016 Source:European Geriatric Medicine Author(s): T. Adamek Recurrence of stroke has been estimated at 3–4% yearly after TIA or stroke. There is no clear agreement in choosing antiplatelet therapy at this time. Europeans, Americans and British guidelines have been different. Aspirin is still used in secondary prevention of ischemic stroke, because of the longest experience with the best-achieved results in different studies and low price. Other used drugs are a combination of aspirin and dipyridamole, P2Y12 receptor antagonists – clopidogrel, ticlopidine, prasugrel an...
Source: European Geriatric Medicine - January 20, 2016 Category: Geriatrics Source Type: research

Comparative Efficacy and Safety of Nine Anti-Platelet Therapies for Patients with Ischemic Stroke or Transient Ischemic Attack: a Mixed Treatment Comparisons
Abstract Anti-platelet treatments, an effective anti-thrombotic therapy, are widely used in non-cardioembolic ischemic stroke or transient ischemic attack (TIA), including aspirin, cilostazol, clopidogrel, and other mono or dual therapies, while the optimal choice remains uncertain. All the literatures of 38 eligible randomized control trials were searched in PubMed, Embase, and China National Knowledge Internet (CNKI) without language limitation. And, nine anti-platelet therapies were assessed, including aspirin, clopidogrel, cilostazol, ticlopidine, triflusal, terutroban, sarpogrelate, dipyridamole plus aspirin,...
Source: Molecular Neurobiology - February 5, 2016 Category: Neurology Source Type: research

When a Single Antiplatelet Agent for Stroke Prevention Is Not Enough: Current Evidence and Future Applications of Dual Antiplatelet Therapy
Opinion statement For secondary stroke prevention, long-term dual antiplatelet therapy is not recommended due to increased bleeding risks. There is no specific evidence for using dual antiplatelet therapy for cervical artery dissection or for adding a second antiplatelet agent after a stroke while taking aspirin monotherapy. For patients with atrial fibrillation and stroke/TIA unable to tolerate warfarin, aspirin monotherapy is reasonable. Dual antiplatelet therapy carries a similar risk of major b...
Source: Current Treatment Options in Cardiovascular Medicine - February 24, 2016 Category: Cardiology Source Type: research

Clopidogrel and Smoking Status Among Ischemic Stroke Patients: Smokers Paradox? (P1.122)
Conclusions: We found that ischemic stroke patients who actively smoked derived a slight yet non statistically significant benefit from clopidogrel compared to aspirin for vascular risk reduction. This issue needs to be further evaluated in additional studies of larger size.Disclosure: Dr. Zhang has nothing to disclose. Dr. Wang has nothing to disclose. Dr. Song has nothing to disclose. Dr. Ji has nothing to disclose. Dr. Hou has nothing to disclose. Dr. Cao has nothing to disclose. Dr. Dong has nothing to disclose. Dr. Huang has nothing to disclose. Dr. Feng has nothing to disclose. Dr. Ovbiagele has nothing to disclose. ...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Zhang, Q., Wang, Y., Song, H., Ji, X., Hou, C., Cao, Q., Dong, K., Huang, X., Feng, W., Ovbiagele, B., Wang, M. Tags: Cerebrovascular Disease: Epidemiology Source Type: research